US Biosimilar Launches About to Turn a Corner

                                                                                          Issue # 3086 | December 10th, 2019      




Advertisement









Advertisement










Advertisement





























Advertisement












Advertisement


































Advertisement
















Advertisement


































Advertisement

News Alert

   

US Biosimilar Launches About to Turn a Corner

The US biosimilar industry has lingered in the shadow of the European market since the US pathway for approvals was initiated in 2009. Ten years later, or less than five years since the first FDA approval of a biosimilar, and just 42% of FDA-approved biosimilars have launched. But in the next three months, a bunch of new biosimilars will hit the market, including new ones in oncology, hinting at a wave of uptake. In fact, if everything stays on schedule, more than 60% of the biosimilars approved in the US will have launched by early next year. The rising number of launches, combined with an increasing amount of quick uptake, may put biosimilar foes on their heels. Learn More
 

   

Sanofi Acquiring Synthorx for $2.5 Billion While  Merck Agrees to Acquire ArQule for $2.7 Billion 

Sanofi has announced that it is acquiring the cancer drug startup Synthorx for $2.5 billion. The 5-year-old startup has been working in the field of synthetic biology, expanding the genetic code to give its researchers more building blocks to create novel drugs. Sanofi said the startup appears to be at the forefront of cancer drug innovation, making it worth the high price tag. While  Merck has announced an agreement to acquire ArQule for roughly $2.7 billion. ArQule is a biopharma company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Learn More about the Sanofi/Synthorx deal or Learn More about the Merck/ArQule deal.
 

   

Amgen Signs 240,000 Sq. Ft. Lease in South San Francisco

BioMed Realty has inked a 240,000-square-foot lease with Amgen at its Gateway of Pacific campus in South San Francisco. The new long-term deal at the 1.3-million-square-foot life science campus that is currently under construction will house Amgen's Bay Area scientists and employees focused on cardiometabolic, inflammation and oncology research. BioMed also recently signed leases with leading innovation companies, including Zymergen for 304,000 square feet to relocate its headquarters to BioMed's Emeryville Center of Innovation in the Bay Area. Learn More
 
Advertisement
Quote Alert


On this Day Alert

2009   "Avatar" Makes its World Premiere in London


On this day in 2009, a 3-D science-fiction epic helmed by "Titanic" director James Cameron, makes its world debut in London and goes on to become one of the highest-grossing movies in history. Starring Sam Worthington, Zoe Saldana and Sigourney Weaver, the box-office mega-hit was praised for its state-of-the-art technology and earned nine Academy Award nominations, including best picture and best director. Learn More

Advertisement
TED Alert

The Biology of Gender, from DNA to the Brain


How exactly does gender work? It's not just about our chromosomes, says biologist Karissa Sanbonmatsu. In a visionary talk, she shares new discoveries from epigenetics, the emerging study of how DNA activity can permanently change based on social factors like trauma or diet. Learn how life experiences shape the way genes are expressed -- and what that means for our understanding of gender. Learn More

Poll Alert

Would you trust a doctor you consulted over the phone or internet?

Yes
No


Advertisement
Bioprocess Alert

Continuous Pharmaceutical Manufacturing: Current Trends and Future Possibilities


This video from the American Pharmaceutical Review on continuous manufacturing, features experts from all facets of the industry including regulatory, manufacturing, and consulting which each share their own unique take on the topic.
 
Market Alert


Advertisement
Event Alert

  

Webinar: Evolutionary Engineering of Microorganisms in Automated Bioreactor Systems

Presented by: Dr. Ir. Robert Mans - Delft University of Technology (TU Delft)

Thursday, December 19th, 2019

Evolutionary engineering of microbes provides a powerful tool for untargeted optimization of (engineered) cell factories and identification of genetic targets for further research. Directed evolution is an intrinsically time-intensive effort and automated methods can significantly reduce manual labor. Those automated methods can be used to evolve yeast cultures for >1,000 generations and are designed to require minimal manual intervention.

Topics:
  • Introduction into why and when to use evolutionary engineering for microbial strain optimization
  • Experimental design considerations for various automated evolutionary engineering cultivation methods
  • Overview of recently developed generic workflows and control software for batch, chemostat and accelerostat based evolution in automated bioreactors


Resource Alert



Modular Design: Implementing Proven Engineering Principles in Biotechnology

Modular design is at the foundation of contemporary engineering, enabling rapid, efficient, and reproducible construction and maintenance of complex systems across applications. Remarkably, modularity has recently been discovered as a governing principle in natural biological systems from genes to proteins to complex networks within a cell and organism communities. The convergent knowledge of natural and engineered modular systems provides a key to drive modern biotechnology to address emergent challenges associated with health, food, energy, and the environment. Here, we first present the theory and application of modular design in traditional engineering fields. Learn More

Advertisement
Regulatory Alert



Regulators Respond After Singapore HSA Recalls Metformin Drugs for NDMA Impurities

Regulators including the US FDA, EMA, Health Canada and the UK's MHRA are looking into whether formulations of the diabetes drug metformin contain N-nitrosodimethylamine (NDMA) impurities. The announcements come after Singapore's Health Sciences Authority (HSA) recalled three out of 46 locally marketed metformin medicines after determining they contained NDMA "above the internationally acceptable level." The three drugs were marketed by Singapore-based Glorious Dexa Singapore and Pharmazen Medicals Pte Ltd. According to HSA, the risk posed by three medicines is low as they "have only been supplied locally for a short period of time since last year." Learn More

Discovery Alert

 

Study Shows Seqirus Flu Vaccine Reduces Hospitalization in Retirement Home Patients

Seqirus has announced the results from a trial led by a team of researchers from Brown University that showed FLUAD ® , an adjuvanted trivalent influenza vaccine (aTIV), was more effective than standard non-adjuvanted trivalent influenza vaccine (TIV) in reducing the risk of all-cause hospitalizations, as well as hospitalization for influenza and pneumonia, in adults 65 years and older living in United States(U.S.) nursing homes during the 2016/17 influenza season.  These findings were presented at the recent National Foundation for Infectious Diseases (NFID) 2019 Clinical Vaccinology Course (CVC), which took place in Washington, D.C. Learn More

Advertisement
Project Alert



Amgen Signs 240,000 Sq. Ft. Lease in South San Francisco

BioMed Realty has inked a 240,000-square-foot lease with Amgen at its Gateway of Pacific campus in South San Francisco. The new long-term deal at the 1.3-million-square-foot life science campus that is currently under construction will house Amgen's Bay Area scientists and employees focused on cardiometabolic, inflammation and oncology research. BioMed also recently signed leases with leading innovation companies, including Zymergen for 304,000 square feet to relocate its headquarters to BioMed's Emeryville Center of Innovation in the Bay Area. Learn More
 
Patent Alert